(Q36854525)

English

Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study

scientific article published on 12 January 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 August 2017

Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study (English)

1 reference

Europe PubMed Central

16 August 2017

0 references

monoclonal antibody

1 reference

based on heuristic

inferred from title

2

object named as

Steven E Nissen

1 reference

Europe PubMed Central

16 August 2017

John J. P. Kastelein

1

object named as

John J P Kastelein

1 reference

Europe PubMed Central

16 August 2017

author name string

Daniel J Rader

3

1 reference

Europe PubMed Central

16 August 2017

G Kees Hovingh

4

1 reference

Europe PubMed Central

16 August 2017

Ming-Dauh Wang

5

1 reference

Europe PubMed Central

16 August 2017

Tong Shen

6

1 reference

Europe PubMed Central

16 August 2017

Kathryn A Krueger

7

1 reference

Europe PubMed Central

16 August 2017

publication date

12 January 2016

1 reference

Europe PubMed Central

16 August 2017

European Heart Journal

1 reference

Europe PubMed Central

16 August 2017

37

1 reference

Europe PubMed Central

16 August 2017

17

1 reference

Europe PubMed Central

16 August 2017

1360-1369

1 reference

Europe PubMed Central

16 August 2017

Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4852062

29 September 2017

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4852062

29 September 2017

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4852062

29 September 2017

The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4852062

29 September 2017

Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4852062

4 September 2018

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4852062

4 September 2018

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4852062

4 September 2018

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4852062

4 September 2018

Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/26757788

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/26757788

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/EURHEARTJ/EHV707

1 reference

Europe PubMed Central

16 August 2017

release_3lxvli6pnfaktojyidnbcl7p3i

1 reference

https://api.fatcat.wiki/v0/release/3lxvli6pnfaktojyidnbcl7p3i

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

16 August 2017

1 reference

Europe PubMed Central

16 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36854525&oldid=2087619837"